tiprankstipranks
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
Holding ACAD?
Track your performance easily

ACADIA Pharmaceuticals (ACAD) Earnings Date & Reports

2,260 Followers

Earnings Data

Report Date
Mar 03, 2025
TBA Not Confirmed
Period Ending
2024 (Q4)
Consensus EPS Forecast
$0.22
Last Year’s EPS
$0.28
Same Quarter Last Year
Moderate Buy
Based on 15 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Nov 06, 2024
|
% Change Since: 6.84%
|
Next Earnings Date:Mar 03, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong sales growth, particularly for Daybue and NUPLAZID, and promising pipeline developments. However, challenges with patient discontinuation, increased expenses, and delayed impact from marketing campaigns were noted. The overall sentiment reflects a positive outlook with some operational challenges.
Company Guidance
During the Q3 2024 earnings call for Acadia Pharmaceuticals, the guidance provided highlighted several key metrics and strategic focuses. Acadia's financial outlook for 2024 includes narrowing the net sales guidance for Daybue to a range of $340 million to $350 million and for NUPLAZID to $600 million to $610 million. The company also revised its NUPLAZID gross-to-net guidance to 26%-27%. Acadia anticipates a cash balance of $600 million to $640 million, excluding the anticipated proceeds from the sale of a priority review voucher, expected to close in Q4 for $150 million, with one-third of the net proceeds owed to Neuren. The company reported $250.4 million in net sales for the quarter, marking an 18% year-over-year increase, and a growing cash position now at $565 million. Acadia remains focused on executing its late-stage clinical trials and continues to explore business development opportunities to drive future growth.
Strong Revenue Growth
ACADIA reported a total net sales increase of 18% from the third quarter of last year, with Daybue and NUPLAZID contributing significantly to this growth.
Daybue Sales Performance
Daybue net product sales were $91.2 million in Q3, up 36% year-over-year and 8% sequentially. This indicates solid market penetration and patient retention.
NUPLAZID Sales Achievement
NUPLAZID achieved net product sales of $159.2 million, marking the highest ever quarterly sales for the brand with a year-over-year growth of 10%.
Pipeline Developments
The company has promising late-stage assets in Prader-Willi syndrome and Alzheimer's disease psychosis, with ongoing efforts in global expansion including recent approval from Health Canada for Daybue.
Financial Strength
ACADIA reported a cash balance increase to $565.3 million, reflecting strong operational performance and cash flow generation.
---

ACADIA Pharmaceuticals (ACAD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ACAD Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 03, 20252024 (Q4)
0.22 / -
0.28
Nov 06, 20242024 (Q3)
0.14 / 0.20
-0.4150.00% (+0.60)
Aug 06, 20242024 (Q2)
0.18 / 0.20
0.011900.00% (+0.19)
May 08, 20242024 (Q1)
0.05 / 0.10
-0.27137.04% (+0.37)
Feb 27, 20242023 (Q4)
0.29 / 0.28
-0.26207.69% (+0.54)
Nov 02, 20232023 (Q3)
-0.45 / -0.40
-0.17-135.29% (-0.23)
Aug 02, 20232023 (Q2)
-0.10 / 0.01
-0.21104.76% (+0.22)
May 08, 20232023 (Q1)
-0.21 / -0.27
-0.761.43% (+0.43)
Feb 27, 20232022 (Q4)
-0.25 / -0.26
-0.273.70% (+0.01)
Nov 02, 20222022 (Q3)
-0.19 / -0.17
-0.09-88.89% (-0.08)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

ACAD Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 06, 2024$15.79$17.20+8.93%
Aug 06, 2024$18.85$15.17-19.52%
May 08, 2024$17.13$15.21-11.21%
Feb 27, 2024$26.36$23.74-9.94%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does ACADIA Pharmaceuticals (ACAD) report earnings?
ACADIA Pharmaceuticals (ACAD) is schdueled to report earning on Mar 03, 2025, TBA Not Confirmed.
    What is ACADIA Pharmaceuticals (ACAD) earnings time?
    ACADIA Pharmaceuticals (ACAD) earnings time is at Mar 03, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ACAD EPS forecast?
          ACAD EPS forecast for the fiscal quarter 2024 (Q4) is $0.22.
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis